Dimitri is looking out.

For today, tomorrow, and the days to come

Dimitri, 31 UNDETECTABLE Started on BIKTARVY® in 2018

Person featured takes BIKTARVY and is compensated by Gilead.

Resistance Data Across 9 Clinical Trials

Explore the BIKTARVY resistance overview

Long-term Treatment-Naïve Efficacy Data

Discover BIKTARVY 5-year efficacy data

5-Year Long-term Safety and Tolerability Profile

Explore BIKTARVY safety data

New Updates for These Special Populations Within the Prescribing Information

Study 4030: Virologically Suppressed Adults, Including Those With Known or Suspected Preexisting M184V/I Resistance Mutation

Explore the data

Study 5310: Virologically Suppressed Adult Women Who Are Pregnant

View the Prescribing Information to learn more about this population


Fueled by the power of bictegravir1

SOURCE: IQVIA LAAD, April 2020 through April 2023*

Real conversations logo.

Hear from key opinion leaders, Joel E. Gallant, MD, MPH, and Calvin J. Cohen, MD, MSc, as they discuss the events that shaped the way providers approach HIV treatment. Drs. Gallant and Cohen are both employees of Gilead.

See Dr. Joel Gallant and Dr. Calvin Cohen discuss more HIV topics:

*This information is an estimate derived from the use of information under license from the following IQVIA information service: IQVIA LAAD, for the period of April 2020 through April 2023. IQVIA expressly reserves all rights, including rights of copying, distribution, and republication.

Reference: 1. Data on file. Gilead Sciences, Inc.